CenterBook Partners
ACRS icon

CenterBook Partners’s Aclaris Therapeutics ACRS Stock Holding History

CenterBook Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-118,228
Closed -$625K – 858
2026
Q2 		$625K Buy
118,228
+51,630
+78% +$230K 0.03% 472
2026
Q1 		$250K Buy
+66,598
New +$225K 0.01% 595

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Three Bridge Wealth Advisors
Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

CenterBook Partners's ACRS Position: Q3 2026 in Review

CenterBook Partners sold out of Aclaris Therapeutics (ACRS) in Q3 2026, closing a stake of 118,228 shares — an estimated $625K sold.

CenterBook Partners first reported a position in ACRS in Q1 2026 and held it in 2 quarters. The position peaked at $625K in Q2 2026. 52 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • CenterBook Partners reported no remaining Aclaris Therapeutics position as of Q3 2026 after selling out during the quarter.
  • CenterBook Partners sold 118,228 Aclaris Therapeutics shares in Q3 2026, an estimated $625K.
  • CenterBook Partners first reported a position in Aclaris Therapeutics in Q1 2026 and held it in 2 quarters.
  • CenterBook Partners's Aclaris Therapeutics position peaked at $625K in Q2 2026.
  • 52 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.